Novartis AG Common Stock (NVS)

Net Receivables

$9.85B

Quarterly · Period ending: · USD

NVS logo

NVS Net Receivables

Latest reported$9.85B
NVS Quarterly Net Receivables ($6.34B → $9.85B)
High-resolution chart · PNG

NVS net receivables history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Novartis AG Common Stock Net Receivables — Quarterly (USD)
Period endingNet Receivables (USD)
9,854,039,000
9,602,000,000
10,934,000,000
8,984,000,000
9,176,000,000
8,725,000,000
8,211,000,000
8,150,000,000
8,480,000,000
8,251,000,000
8,123,984,003
7,099,000,000
9,543,000,000
9,183,000,000
8,936,021,625
8,680,000,000
8,910,000,000
8,678,000,000
8,828,000,000
8,632,000,000
8,654,000,000
8,481,000,000
9,073,000,000
8,299,000,000
7,952,000,000
8,795,000,000
9,171,960,358
8,070,000,000
8,252,000,000
7,845,000,000
9,676,000,000
8,766,000,000
8,989,000,000
9,116,000,000
10,070,000,000
8,482,000,000
8,380,000,000
8,234,000,000
10,202,000,000
8,547,000,000
8,606,000,000
8,464,000,000
8,180,000,000
8,495,000,000
8,750,000,000
8,794,000,000
10,255,000,000
8,857,000,000
9,371,000,000
10,324,000,000
9,902,000,000
10,502,000,000
10,792,000,000
10,484,000,000
11,108,000,000
10,519,000,000
10,487,000,000
10,605,000,000
12,373,000,000
10,703,000,000
10,915,000,000
10,861,000,000
11,716,000,000
10,391,000,000
7,798,000,000
7,773,000,000
10,010,000,000
7,817,000,000
7,167,000,000
6,751,000,000
8,573,000,000
7,251,000,000
7,142,000,000
6,883,000,000
8,504,000,000
6,813,000,000
6,233,000,000
6,353,000,000
7,971,000,000
6,087,000,000
5,885,000,000
5,292,000,000
6,563,000,000
5,137,000,000
5,091,000,000
4,858,000,000
6,189,000,000
4,492,000,000
4,482,000,000
4,326,000,000
5,480,000,000
4,253,000,000
4,259,000,000
3,928,000,000
3,707,000,000
3,664,000,000
3,612,000,000
3,228,000,000
4,726,000,000
3,221,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.